Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03136497 · ClinicalTrials.gov registry record · Phase 1
A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Phase 1 study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03136497 is a Phase 1 study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 10 participants.
The verdict
NCT03136497, a Phase 1 study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
A Study of Venetoclax Plus Ibrutinib and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL). Our hypothesis is that the combination therapy of BTK (Bruton's tyrosine kinase) Inhibitor Ibrutinib plus Venetoclax and Rituximab in relapsed or refractory DLBCL will have an increased activity with acceptable toxicity. Furthermore, this new novel therapeutic combination will be safe and well tolerated among this patient population.
Interventions
- DRUG Rituximab
- DRUG Ibrutinib
- DRUG 400mg ABT-199
- DRUG 800mg ABT-199
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2020-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03136497
The ClinicalTrials.gov registry entry for NCT03136497 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rituximab is the first listed.
NCT03136497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03136497 about?
NCT03136497 is a clinical study titled "A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma". A Study of Venetoclax Plus Ibrutinib and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL). Our hypothesis is that the combination therapy of BTK (Bruton's tyrosine kinase) Inhibitor Ibrutinib plus Venetoclax and Rituximab in relapsed or refractory DLBCL will have...
What is the current status of trial NCT03136497?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-09-05. Estimated completion is 2020-11-09.
What interventions are being tested in trial NCT03136497?
The interventions under investigation include: Rituximab (DRUG), Ibrutinib (DRUG), 400mg ABT-199 (DRUG), 800mg ABT-199 (DRUG).
Who is sponsoring clinical trial NCT03136497?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.